Skip to content

BioSig Launches PURE EP™ Software program Model 6 with ACCUVIZ™ Module

Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) –BioSig Applied sciences, Inc. (NASDAQ: BSGM) (“BioSig” or the “Firm”), a sophisticated digital sign processing know-how firm delivering unprecedented accuracy and precision to intracardiac sign visualization with its proprietary PURE EP™ System, as we speak introduced the discharge of PURE EP™ Software program Model 6 with ACCUVIZ™ Module.

Constructed round three extremely differentiating options, PURE EP™ Software program Model 6 with ACCUVIZ™ Module introduces the proprietary Excessive Frequency Algorithm (HFA), a novel characteristic that identifies the important thing frequency parts of cardiac information that may be troublesome to establish throughout the conventional waveform presentation . Different distinctive software program functionalities—together with Automated Tachycardia Characterization (ATC) and TRUSOURCE Evaluation & Report—intention to enhance scientific workflow and ship clear, actionable insights to as we speak’s electrophysiologist.

PURE EP™ Software program Model 6 with ACCUVIZ™ Module is the primary to be designed and launched by the Firm’s new business and operations crew and represents essentially the most superior iteration of the Firm’s digital sign processing know-how. Software program Model 6 delivers a brand new stage of effectivity enabling limitless, real-time evaluation of intracardiac indicators. As well as, the brand new ACCUVIZ™ Module introduces superior sign processing automation, elevated visualization of clear cardiac sign data, and even smarter workflows.

“PURE EP™ Software program Model 6 with ACCUVIZ™ Module acquires uncooked intracardiac indicators of their digital kind to supply a brand new stage of effectivity and automaticity. I view this as a milestone within the scientific evolution of our know-how, and a testomony to our mission to supply our clients with actionable insights,” commented Grey Fleming, Chief Commercialization Officer, BioSig Applied sciences, Inc.

BioSig will introduce the latest software program model of its PURE EP™ System to clients—for the primary time—on the annual Cleveland Clinic World EP Summit 2022. The annual symposium is happening this Friday-Saturday, September 23-24, 2022, in Cleveland, Ohio. The Firm has been invited to attend the world-class management symposium as a platinum sponsor for the occasion.

In regards to the World EP Summit

The World EP Summit is an annual discussion board convening over 40 world EP specialists to spotlight the most recent analysis, technological developments, and state-of-the-art practices within the discipline of arrhythmia administration. Co-sponsored by the Cleveland Clinic and the Coronary heart Rhythm Society, the 1.5-day program is designed for, however not restricted to, cardiologists, electrophysiologists, cardiovascular fellows, electrophysiology fellows, nurses, PAs and all healthcare suppliers concerned within the care of arrhythmia sufferers.

About BioSig Applied sciences

BioSig Applied sciences, Inc. is a sophisticated digital sign processing know-how firm bringing never-before-seen insights to the remedy of cardiovascular arrhythmias. Via collaboration with physicians, specialists, and healthcare leaders throughout the sphere of electrophysiology (EP), BioSig is dedicated to addressing healthcare’s largest priorities — saving time, saving prices, and saving lives.

The Firm’s first product, the PURE EP™ System, an FDA 510(okay) cleared non-invasive class II system, offers superior, real-time sign visualization permitting physicians to carry out insight-based, extremely focused cardiac ablation procedures with elevated procedural effectivity and efficacy.

The PURE EP™ System is at present in a nationwide business launch and an integral a part of well-respected healthcare programs, comparable to Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas Metropolis Coronary heart Rhythm Institute. In a blinded scientific research not too long ago printed within the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equal or superior to traditional programs for 93.6% of sign samples, with 75.2% incomes a superior score.

The worldwide EP market is projected to achieve $16B in 2028 with a 11.2% progress charge.

Ahead-looking Statements

This press launch comprises “forward-looking statements.” Such statements could also be preceded by the phrases “intends,” “could,” “will,” “plans,” “expects,” “anticipates,” “tasks,” “predicts,” “estimates,” “goals,” “believes ,” “hopes,” “potential” or comparable phrases. Ahead-looking statements will not be ensures of future efficiency, are primarily based on sure assumptions and are topic to numerous identified and unknown dangers and uncertainties, a lot of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes could differ. materially from these expressed or implied by such forward-looking statements. Such dangers and uncertainties embody, with out limitation, dangers and uncertainties related to (i) market situations and the Firm’s supposed use of proceeds, (ii) the geographic, social and financial affect of COVID-19 on our means to conduct our enterprise and lift capital sooner or later when wanted, (iii) our incapacity to fabricate our merchandise and product candidates on a business scale on our personal, or in collaboration with third events; (iv) difficulties in acquiring financing on commercially affordable phrases; (v) adjustments within the measurement and nature of our competitors; (vi) lack of a number of key executives or scientists; and (vii) difficulties in securing regulatory approval to market our merchandise and product candidates. Extra detailed details about the Firm and the danger components that will have an effect on the conclusion of forward-looking statements is ready forth within the Firm’s filings with the Securities and Change Fee (SEC), together with the Firm’s Annual Report on Type 10-Ok and its Quarterly Studies on Type 10-Q. Buyers and safety holders are urged to learn these paperwork freed from cost on the SEC’s web site at http://www.sec.gov. The Firm assumes no obligation to publicly replace or revise its forward-looking statements on account of new data, future occasions or in any other case.


Andy Ballou
BioSig Applied sciences, Inc.
Vice President, Investor Relations
55 Greens Farms Highway
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

Primary Logo

.

Leave a Reply

Your email address will not be published.